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ABSTRACT 
This study examined outpatient disability in chronic low back pain (cLBP), assessed 
whether patients received treatment, and clinicians’ prescribing habits. 
Methods and materials: This prospective, single-centre cross-sectional study was 
conducted from the 1st of July to the 31st of October 2016. An Oswestry Disability 
questionnaire (ODI) and medical records were surveyed in 279 participants. 
Results: The median ODI was 48.9%. More than 50% of patients reported ‘fairly 
severe’ to ‘very severe’ pain that significantly limited walking distance and ability to 
lift objects. In contrast, standing, sitting, travel and social life were relatively 
unaffected. Paracetamol was readily available 23% of the time, non-steroidal anti-
inflammatories 46%, and opioid-like drugs 7%. 
Discussion: The above average ODI and its discrepant impact on Activities of Daily 
Living may be due to drug shortages with patients judiciously self-dosing for selected 
activities. 
Conclusion: Pain significantly disabled participants. Essentially all drugs underwent 
shortages despite clinician compliance with evidence-based protocols. 
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1. CHAPTER ONE: INTRODUCTION AND LITERATURE 
REVIEW 
1.1. General Introduction  
The primary purpose of this study is to objectively analyse functional outcomes 
following treatment of chronic low back pain (cLBP) in patients attending the Chris 
Hani Baragwanath Academic Hospital (CHBAH) Orthopaedic Spine Outpatients 
Department (OPD) based in Soweto, South Africa (SA). The study also assesses 
whether patients receive medicines as prescribed to manage their cLBP.  
The secondary aims of the study are to determine which specific drugs and drug 
classes are affected by problematic pharmacy supplies and evaluate the extent of 
these issues. The study also analyses orthopaedic clinicians’ prescribing habits. 
1.2. Definitions 
(i)  Low back 
Anatomically, the ‘low back’ is the area in the posterior aspect of the body from the 
lower margin of the twelfth ribs to the lower gluteal folds1.  
 
(ii)  Low back pain (LBP) 
LBP is an “activity-limiting low back discomfort that may be referred into one or both 
lower limbs2.”  
 
(iii)  Chronology of LBP  
 Acute LBP lasts less than 4 weeks3.   
 Sub-acute LBP lasts 4 to 12 weeks3. 
 Chronic LBP (cLBP) implies ongoing symptoms of greater than 3 months’ 
duration4. 
 
(iv)  Oswestry Disability Index (ODI) 
The ODI was developed over several years by O’Brien et al. in 19805. It is a 
condition-specific, validated tool used to measure patient outcomes in spine disease, 
and is based on self-reported symptoms representing the impact of spine disease in 
up to ten aspects of their lives5.  
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The ODI is used in acute, subacute and chronic spine disease, and is considered the 
‘gold standard’ in assessing functional capacity as well as measures outcomes of 
therapy in LBP5. All ten questions follow a similar format and all have six possible 
answers. The first question, for example, specifically analyses the participant’s 
subjective experience of pain. Participants are required to describe their pain as 
either: ‘non-existent’, ‘mild’, ‘moderate’, ‘severe’, ‘very severe’ and ‘the worst 
imaginable’. Each response in the ODI is allocated an individual score between zero 
and five. Increased severity is denoted by incrementally higher scores allocated to 
progressively worsening responses to each question.  
Additional questions in the ODI analyse patient personal care, ease of lifting items, 
walking, sitting, standing, sleeping, sex life (an optional question), social life and 
ability to travel. At completion, each question’s response is scored, and the final 
score tallied and divided by 50 (or 45 if the patient omits optional question 8 on their 
sex life). This total is then multiplied by 100 to obtain a percentage. 
This percentage may fall into five possible categories of disability, ranging from ‘mild 
disability’ (0 - 20%), ‘moderate disability’ (21 - 40%), ‘severe disability’ (41 - 60%), 
‘crippled’ (61 - 80%) and ‘bed-bound’ (81 - 100%)5.  
(v)  Disability  
The International Classification of Functioning, Disability and Health (ICF) manual 
prescribes disability as a broad description of a dynamic limitation to function - 
relative to potential capacity - within each patient’s environment6, 7. 
 
(vi)  Drug stock outs, shortages and substitutions  
A ‘stock out’ implies complete unavailability of medication. A ‘shortage’ occurs when 
a drug is available in smaller than adequate drug volumes to meet predicted 
demand. In response, pharmacists may ration all quantities of medication dispensed 
- giving patients fewer doses than what is prescribed by the clinician – in a bid to 
ensure wider distribution of the same8. Should a pharmacist dispense an alternative 
drug in the same class - in lieu of a clinician-prescribed drug that is out of stock - a 
drug ‘substitution’ is noted. 
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(vii)  Patient records 
The patient’s record is his/her individual medical file. In the Spine OPD at CHBAH, 
patient records are manually maintained with handwritten entries in chronological 
order. These records include medically relevant data, including the patient’s 
prescribed medications to take home (T.T.O.) and volumes of drugs dispensed.  
1.3. Background 
1.3.1.  Economic Impact of Low Back Pain 
Chronic LBP contributes significantly to the global burden of disease as one of the 
top two reasons for medical consultation9, 10. Pain’s debilitating nature cannot be 
overstated. It is the world’s principal precipitant for activity limitation, work absences 
and the greatest contributor to disability globally9.  
Although cLBP’s wide scale economic impact in SA has not been fully explored, it 
has been estimated to run into the millions per annum11. Developed nations, such as 
the United Kingdom (UK), estimate that up to 20% of their annual health care budget 
is disbursed in the management of cLBP. Chronic LBP has a larger effect on their 
economy than most other medical conditions - exceeding costs attributed to most 
other illnesses within the UK12-15.  
Eighty five percent (85%) of the cost to global economies from cLBP is 
predominantly due to indirect costs, such as lost productivity from incapacity, 
absenteeism and the affected individuals potentially leaving the labour market 
prematurely. LBP’s direct costs are linked to the investigation and treatment of the 
condition12, 16.  
LBP beleaguers individuals across socioeconomic classes and political confines13 
and demonstrates a high incidence and prevalence in all populations2, 17. If anything, 
LBP has an increased incidence in low and middle-income countries, with a 
prevalence predicted to increase ‘substantially’ in these nations within the next few 
years10, 14, 18, 19. Chronic LBP is both common and recurrent, with an adult prevalence 
up to 84%, peaking at around 80 years of age20. 
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1.3.2. Consequences and Dilemmas in Pain Management 
The impact of pain on livelihoods is so significant, that its treatment has been upheld 
in the Universal Declaration of Human Rights, as a fundamental human right21.  
In failing to have symptoms of pain adequately managed by health care 
professionals, both patient satisfaction and their health-seeking behaviour is 
negatively impacted22. Patients generate maladaptive health seeking patterns and 
become increasingly reluctant to attend to their pain and other health problems22.  
Additionally, clinicians and hospitals, both earn a poor reputation, with medical 
professionals on the receiving end of successful litigation for poor management of 
pain in their patients23. Partly responsible for this situation is the wanting 
undergraduate clinician training that has historically been sorely lacking in 
comprehensive instruction relating to the pathophysiology and management of 
pain24.  
Several studies around pain management in cancer patients within SA have 
demonstrated ‘relatively good’ analgesic availability, when pitted against most 
nations on the continent, and globally25, 26, while, locally CHBAH has been reported, 
according to the Gauteng Member of the Executive Committee, to have attained 
96% of the National Core Standards (NCS)27, 28. This suggests outstanding service 
with respect to patient’s Rights to access well-managed pain29 and health care30.  
In spite of this promising information, several anecdotal word-of-mouth reports at 
CHBAH (and other SA medical centres), have suggested that patients frequently 
experience difficulty in receiving their prescribed T.T.O.’s31-33. Spurred on to improve 
service delivery, the Department of Health (DoH) in South Africa has tackled these 
hurdles with the implementation of several novel approaches to avert inadequate 
drug supplies34-36. 
1.4. Regional anatomy and pathoanatomy of LBP  
1.4.1. Degenerative Changes in the Spine 
The lower back consists of the 5 lumbar vertebrae, which transmit the spinal cord, 
conus medullaris and nerve roots. Unique to this region of the spine is its flexibility - 
a distinction that allows movement of the spine in several planes. To accommodate 
this particular capacity, the lumbar vertebrae are connected by strong ligaments: the 
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anterior longitudinal ligament, posterior longitudinal ligament and ligamentum flavum.  
In addition, facet joints and intervertebral discs (IVD) between the vertebrae 
contribute to stability, dissipate stresses on the spine and permit movement. The 
IVDs consist of a peripheral ring of lamellar collagen called the annulus fibrosus (AF) 
that surrounds a proteoglycan rich nucleus pulposus. The AF is peripherally 
innervated by a meningeal branch of the relevant spinal nerve at each vertebral 
level20, 37. IVDs and facet joints are both potential sources of LBP. Degeneration of 
IVDs leads to instability of the spine, hypermobility of the same, disc herniation, 
hypertrophy of the ligamentum flavum, facet hypertrophy, and subsequent 
generation of osteophytes, causing back pain and functional limitation38. 
1.4.2. Patho-mechanics of Low Back Pain 
(i) LBP, Aging and Body Habitus 
In the general population, LBP may be caused by myriad factors, alone, or in 
combination, such as poor muscle tone, inactivity/overexertion or muscle sprain, 
malignancy, fracture of the vertebra(e), radiculopathy, pain secondary to spinal 
surgery, myofascial pain syndromes, or as a result of referred pain – (from the 
kidneys, sacroiliac joint) among others.  
 
With age, patients undergo sarcopaenia – a condition wherein muscle mass is 
progressively replaced by adipose tissue. They ultimately lose muscle strength and 
struggle with mobility39. With an increase in - or exacerbation of - co-morbidities, the 
subsequent weakness predisposes patients to an increased risk of injury, both within 
and without the musculoskeletal system (MSS) 39, 40. Repetitive MSS micro-trauma in 
older adults generates an increase in inflammatory mediators – mediators that have 
been associated with poor function41.  
 
On the other hand, lifestyles in modern, developed cities have become increasingly, 
and irrevocably, paired with sedentary lifestyles. Urbanites spend a significant 
portion of their time sitting at work, in travel and in leisure. This sedentary lifestyle is 
to blame, in part, for the obesity epidemic currently sweeping the globe. Obesity 
values, determined using Body Mass Indices (BMI), suggest that women in SA are 
particularly vulnerable. With up to 59.4% of women estimated to be overweight or 
6 
 
obese42, this increased mechanical loading on the spine ramps up South African 
women’s risk of LBP43-45. 
(ii) Posture 
Sitting may ameliorate LBP by relatively widening the spinal canal. Similarly, leaning 
forward (manoeuvres such as the “shopping cart sign”) improves LBP symptoms 
through the mechanics of spine flexion, hip flexion and anterior pelvic flexion. A 
posture that stretches the ligamentum flavum and enlarges the foramina46.  
 
LBP may, conversely, also be provoked by prolonged sitting. Through prolonged 
flexion of the lower back, this posture places strain on the posterior elements of the 
spine, and causes sustained low level muscle strain resulting in muscle fatigue and 
pain47. 
 
When standing, the sagittal alignment of the lumbar spinal cord is lordotic, and - if 
already narrowed by degenerative changes - further diminishes in size. This is in line 
with Penning’s Rule of Progressive Narrowing48. In this manner, standing may 
exacerbate LBP. 
 
Walking is a dynamic movement that has a variable effect on low back pain 
depending on several variables, including arm swing, walking cadence, gait pattern, 
presence of pathology in lower limbs and/or spine, ground inclination and others48, 49.  
 
Patients with LBP typically walk at a slower pace50. Kinematics studies reveal that 
slow gait exacerbates low back pain through decreased lumbar spine 
flexion/extension, twisting or lateral bending. This reduced movement results in 
constant and increased spine loading49. In contrast, fast gait may improve low back 
pain through relative lumbar spine flexion, increased movement of the spine and 
increased activation of trunk muscles49. 
  
Lying supine removes mechanical loading from the lumbar spine - hence the relief of 
pain symptoms. When a patient lifts an object, a variable burden (dependent on the 
weight of the object, among other factors) is placed on the spinal column. This 
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additional pressure increases spinal loading, invariably narrowing the lateral 
recesses, eliciting pain in predisposed patients48, 51. 
1.5. Current Concepts in the Pathophysiology of Pain 
Pain is considered by some as a disease process in its own right. Inadequate 
management may result in several systemic adverse outcomes in response to pain 
symptoms52-61: 
 The endocrine system releases several catabolic enzymes (cortisol, glucagon, 
growth hormone, catecholamines, etc.) that affect carbohydrate, protein and 
fat metabolism via the hypothalamic-pituitary-adrenal axis. 
 Sympathetic Nervous System (SNS) activity is ramped up with a knock-on 
effect on the cardiovascular system (CVS) evidenced by tachycardia, raised 
peripheral vascular resistance and blood pressure rendering the heart prone 
to ischemia and infarction.   
 The lungs have a decreased vital capacity as the patient suffers 
diaphragmatic dysfunction resulting in impaired ventilation, weak cough 
reflexes, atelectasis, infections, hypoxia and hypercarbia. 
 Intestinal secretions and sphincter tone increases, generating nausea, 
vomiting, impaired gastrointestinal tract (GIT) function and ileus through 
decreased intestinal motility.  
 The urinary system is affected by the increased sphincter tone, urine retention 
and oliguria. 
 Coagulation pathways are affected: there is increased platelet aggregation, 
venostasis and a subsequent increased risk of deep vein thrombosis (DVT) 
and thromboemboli. 
 MSS weakness, fatigue, muscle atrophy and reduced range of movement 
lead to atelectasis, and decubitus ulcers. 
 Psychologically, pain induces anxiety, anger, depression, fear and even 
suicidal tendency.  
Lastly, Human Immunodeficiency Virus (HIV) may exacerbate the incidence of LBP 
through HIV Associated Neuropathy (HIVAN)62, 63. The SA population is burdened 
with the highest global burden of HIV - an estimated 7 million people live within our 
borders with the virus64. HIV Associated Neuropathy is associated with the use of 
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Highly Active Antiretroviral Therapy (HAART), in particular, regimens including 
stavudine24.  
1.6. Guidelines and Medications in the Treatment of cLBP 
1.6.1. Current Literature 
Previously, the World Health Organisation’s (WHO) Ladder of Pain Control proposal 
in 198665 laid the foundation for the general principles of pain management 66.  
The latest guidelines (November 2016) from the National Institute for Health Care 
Excellence (NICE) recommend initial screening of patients to exclude ‘specific’ 
causes of LBP  such as malignancy, infection, trauma and other ‘Red Flags’67. 
Baseline assessment of disability is conducted at first contact to stratify patient care. 
Selective use of radiographic investigations is made if likely to change treatment and 
psychoeducation is administered. 
On physical therapies, physical training and manipulation of the spine are 
suggested3, 68, while medical management consists of oral Nonsteroidal Anti-
inflammatory Drugs (NSAIDS) - with respect to pre-existing patient co-morbidities 
and potential complications. If NSAIDS are intolerable or contraindicated, weak 
opioids may be administered68.  
Opioids are to be avoided, as is paracetamol alone. Potential additional therapies 
include epidural blocks and local anaesthesia, surgical decompression and 
denervation. After one year, if symptoms persist, these patients are to be down 
referred to primary care facilities as well as a pain clinic where warranted67. 
In the presence of sciatica, antiepileptic medication may be prescribed and epidural 
injections and/or surgical decompression may be performed.  
American College of Physicians (ACP) guidelines, released in April 2017 provides 
similar guidelines, endorsing paracetamol (in combination with other drugs)68, 
NSAIDS, weak opioids3 as first line therapy as well as physical therapies and muscle 
relaxants68, but did not consider radiculopathy and surgery in their guidelines. 
Second line therapy included tramadol and duloxetine while opioids could be 
considered if first and second line therapies had failed and the benefits outweigh the 
risk3, 69. 
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1.6.2. Drugs 
(i) Paracetamol 
Paracetamol is commonly prescribed as first line therapy for pain as recommended 
in the Essential Drugs List (EDL) of SA and the WHO’s analgesic ladder70. More 
recently, several studies have shown that it may not be as effective as once thought 
in both acute and cLBP. In addition to paracetamol’s questionable efficacy are 
concerns about the safety of paracetamol when consumed by patients at optimal 
doses. Side effects such as hepatotoxicity, renal dysfunction, increased risk of 
myocardial infarction and high blood pressure have been documented70-72. 
 
(ii) NSAIDS 
By inhibiting the crucial cyclooxygenase (COX) enzymes through the administration 
of NSAIDS, inflammation and pain are prevented by the inhibition of prostaglandins. 
There are two types of NSAIDS: selective (COX-1 enzyme inhibitors) and non-
selective (COX-1 and COX-2 inhibitors)73. While the literature on NSAID efficacy has 
been contradictory, a recent meta-analysis of 13 Randomised Control Trials (RCTs), 
all NSAIDs showed a slight improvement in pain and disability symptoms73. 
However, NSAIDs’ potentially lethal side effects (cardiovascular risk and GIT73), 
must be borne in mind when prescribing NSAIDs73.  
 
(iii) Opioids 
Weak opioids occupy the second step in the WHO analgesic ladder. Codeine is a 
weak opioid used for the management of chronic pain, however its effectiveness is 
controversial and studies, to date, have not been of sufficient quality to indicate, or 
dissuade against, its use74, 75. There is the accompanying potential for opioid abuse 
and dependency, among other side effects such as nausea, constipation, sedation - 
increasing the risk of falls76.  
 
(iv) Opioid-like drugs 
With a mechanism of action similar to opioids, drugs within this class - such as 
tramadol - have been shown to have a better side effect profile than opioids with 
reduced pain and improved functional outcomes74, 76. Tramadol is a synthetic opioid 
whose mechanism of action involves activity at μ (mu) receptors as well as inhibiting 
the reuptake of serotonin and noradrenalin77.  
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Tramadol is also the only drug that has been found in clinical trials to unequivocally 
improve fibromyalgia symptoms at doses of 200-300mg per day78 with these 
improvements replicated in cLBP studies79. Tramadol, however, reduces the seizure 
threshold – particularly in combination with the use of neuroleptics and 
antidepressants and its addictive potential80. 
 
(v) Combinations 
This class is a miscellaneous collection of various drug combinations of various 
ratios including paracetamol, NSAIDS, opioids and opioid-like drugs.  
 
(vi) Muscle relaxants 
Although this class of drugs has been used in the management of LBP 3, 81 – its use 
remains controversial due to a paucity of data on long-term outcomes and a poor 
evidence base supporting its use81.  
 
(vii) Topical analgesics 
These drugs were developed for use in patients in whom oral therapies would 
compromise their clinical condition. Methyl salicylate – known locally as ‘rub rub’ or 
‘wintergreen’ - is closely related to acetylsalicylic acid. Theoretically ‘rub rub’ 
increases the risk of distal mucosal bleeding, but these side effects have not been 
pronounced in literature82. 
Rubefacients provide relief through a counter-irritant effect effecting either a cooling 
or warming effect on overlying skin82, but there is limited evidence supporting their 
widespread use for clinical indications outside of soft tissue injuries and chronic joint-
related conditions83.  
 
(viii) Antiepileptics 
Despite the paucity of literature, topiramate has been shown in several studies to 
improve symptoms in LBP effecting stable moods and weight loss alongside its 
direct effects on central pain pathways84. 
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(ix) Antidepressants 
Although the quality of studies and type of antidepressant assessed has varied, 
several placebo-controlled RCTs on duloxetine (Cymbalta) have shown a statistically 
significant improvement in symptoms85. Tricyclic antidepressants (TCA’s) and 
Selective Serotonin Reuptake Inhibitors (SSRI’s) are the two antidepressant classes 
typically used to supplement first- and second-line medical management of cLBP.  
 
Antidepressants are believed to act centrally by inhibiting the reuptake of 
neurotransmitters (noradrenaline and/or serotonin)86. Through these pathways they 
modulate central as well as peripheral nociception, neural transmission and 
sensitisation to pain86. TCA’s (the category to which amitriptyline belongs) are the 
more effective class of the two antidepressants87. Amitriptyline works at doses much 
lower (25 - 50mg) than those used in treating major depressive disorders (100 - 
300mg) without inducing its mood-altering effects and avoiding side effects88. 
 
(x) Antipsychotics 
Although studies of antipsychotics as add-on therapy for management of acute and 
chronic pain support their benefits, extrapyramidal and sedating side effects are 
major concerns in their use89. 
1.7. Measurement and Interpretation of Outcomes  
The ODI is a popular outcome measure used by clinicians in patients suffering from 
back pain to assess a baseline at the commencement of therapy and monitor 
response to intervention.  
The average ODI in ‘normal’ patients is 10.195. Serial ODI tests should be done on 
LBP patients to assess improvement. The minimum clinically meaningful response to 
therapy is a decreased score of at least 30% or 10 points15, 90.  
1.8. Healthcare Standards and Challenges  
With regards to the provision of quality healthcare, the NCS has set measures 
against which standards are upheld within SA public hospitals27, 28, 30. Comprised of 
several aspects, the domain of ‘Patient Rights’ upholds citizens’ right to access 
healthcare30, ‘Patient Care’ upholds protocol-directed management of medical 
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conditions and ‘Clinical Support Services’ encompassing pharmaceutical services 
(procurement, stock control, and dispensing medication)28, 30, 66. 
In response to this inefficient ‘Clinical Support’, repeated drug supply chain failures 
have occurred. To ameliorate this, ‘Operational Management’ tools and surveillance 
programs have been instituted by the DoH recently, namely30, 34-36, 91: 
 Pipeline Analysis (PAI): launched in 2015 is a world first. Designed to allow 
provincial health departments’ direct access to information on drug availability, 
it aids in projecting delays in supply and acts as an early warning system 
triggered by potential shortfalls in drug supply. 
 Stock Visibility System (SVS): alerts central databases of drug shortages or 
overstock 
 Rx Solution: stock management software 
Reports compiled by surveillance organisations - such as the Stop Stock Outs 
Project (SSP) and several mainstream media outlets have documented concerns 
that several essential medicines are being found perpetually unavailable in adequate 
quantities or completely inaccessible36 30, 34-36, 91. SSP has verified and published 
these reported, countrywide shortages at various medical facilities, documenting 
supply issues spanning several months at a time - or, in some instances - several 
times in a year8. 
Criticism of these shortages - despite the tools in place to mitigate these events as 
indicated earlier in this study - points the finger at several domains, suggesting 
financial and logistical mismanagement through unpaid suppliers, incorrect deliveries 
and poor forecasting of drug demand36. 
1.9. Research Questions 
i. What is the disability status of patients treated at the orthopaedic spine 
outpatient department at CHBAH for cLBP? 
ii. What is the pain intensity experienced by cLBP patients managed at CHBAH? 
iii. What is the availability of prescribed medication for outpatients managed at 
CHBAH and what are the treating clinicians’s prescribing habits? 
13 
 
1.10. Research Objectives 
i. To perform a cross sectional analysis of impairment in patients suffering from 
cLBP through their responses to the Oswestry Disability Index questionnaire. 
By summing their overall score, to allow their classification into various 
classes of disability. 
ii. To individually assess various activities of daily living and their correlation to 
age, gender, pain and disability. 
iii. To analyse how readily available analgesia is at the CHBAH pharmacy once it 
has been prescribed by clinicians.  
iv. To analyse what drugs and their quantities are dispensed to determine access 
to medication and clinicians prescribing habits. 
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2. CHAPTER TWO – METHODS AND MATERIALS 
2.1. Ethics 
The study was approved by the Human Research Ethics Committee (Medical) at the 
University of the Witwatersrand, and designated clearance number M160406 
(Appendix F). Permission to conduct research and access relevant patient records 
was granted by the Medical Advisory Committee, CHBAH (Appendix G). 
2.2. Study design 
This was a prospective, single-centre cross-sectional study of outpatients receiving 
treatment for non-specific LBP at a tertiary level hospital in Johannesburg, SA. 
2.2.1. Study setting 
Founded in 1941, CHBAH is based in Soweto, SA, and is one of the world’s largest 
hospitals92. It is a tertiary institute that serves a population of approximately three 
million, within and without the local community south of Johannesburg. CHBAH 
welcomes over two thousand outpatients daily93, and over half a million patients 
annually94. Approximately 17% of these patients are referred to the orthopaedic 
outpatient clinics95, 96.The Spine Unit - one of six sub-specialist services provided by 
the Department of Orthopaedic Surgery at the hospital - runs a general outpatient 
clinic once a week, attending to approximately one hundred patients97.  
These patients are referred to the spine OPD from primary care facilities, 
neighbouring secondary facilities and other OPD departments within CHBAH. 
Usually they are commenced on treatment and referred for reassessment. No ODI is 
administered at these referring institutions, nor is it standard procedure to document 
a baseline or follow-up ODI at first contact with spine clinic doctors. 
2.2.2. Study population and sampling 
The study enrolled two hundred and eighty two (282) existing outpatients known to 
the spine clinic between the 1st of July 2016 and the 9th of September 2016.  
The participants were selected using simple randomization. Patients were 
approached at varied points in the queue at the spine OPD while awaiting their 
consultation with the orthopaedic clinician, and had the study explained to them. 
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After counselling, if individuals accepted enrolment, they were subsequently 
consented and the same documented (Appendices A and B). 
2.2.3. Selection criteria 
Inclusion criteria 
 At least 18 years of age 
 Existing CHBAH spine unit patient attending the spine clinic served by the 
Department of Orthopaedic Surgery, CHBAH between 1st of July 2016 to 9th of 
September 2016 
 LBP symptoms lasting more than 12 weeks 
 
Exclusion criteria 
 Prisoners or other institutionalised individuals 
 Significant or poorly controlled medical conditions requiring immediate 
intervention 
 Pregnant patients 
 Patients with known, treatable spine conditions 
 Incomplete data collection sheets 
 
2.3. Recruitment 
The target population was patients with existing LBP being attended to at the 
CHBAH spine OPD. 
Patients were approached individually at the OPD clinic at their follow-up 
appointment and were recruited by Dr. Anne Maina, the Principal Investigator (PI), 
with the aid of a research assistant and/or staff nurse to translate where the patients’ 
grasp of English was poor or for patients who preferred to converse in their native 
tongue.  
A source document tracking the names of the clinical and research staff that 
obtained informed consent and specific details of the same was filled for each 
enrolled patient (Appendix C).  
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A hard copy of the patient consent (signed by the patient, PI and witness) permitting 
administration of the ODI as well as access to their records was safely filed by the PI 
for data capture (Appendices A and B). 
Data were prospectively collected from each patient themselves. The ODI, a 
validated questionnaire was filled out by each enrolled patient with responses based 
on symptoms experienced at the time of presentation and within the preceding seven 
days (Appendix D). 
2.4. Informed consent 
Patients were counselled on the purpose of the study and their right to refuse or 
rescind consent, then, or at any time during the study. Hard copies describing the 
study and contact information pertaining to queries about the study and ethics 
approvals (for the PI and ethics committee) were given in person to the patients to 
take home for their reference (Appendix A). Once consent was obtained, this was 
documented in writing by both the patient (signed consent, including a witness to the 
same) and PI (Appendix C). 
2.5. Data Collection and Capturing 
2.5.1. Oswestry Low Back Pain Disability Questionnaire 
Relevant identifiers and epidemiological data (patient’s name, hospital number, age 
and sex) were captured at the top of the ODI questionnaire (Appendix D).  
Patients presented themselves to the Records Department on the morning of their 
Spine OPD consultation with their appointment card as proof of their scheduled 
follow-up. Clerks gave the respective files to patients in person and directed them to 
queue in the orthopaedic OPD area for their appointment. 
Patients were approached for enrolment from the Spine OPD area and, upon 
consenting to enrolment in the study, received a pen and version 2.1a5 of the ODI 
questionnaire in English, which they filled out while waiting in queue.  
Patients illiterate in English were assisted in completion of the ODI which was 
administered verbally to them and documented by the PI. The distance walked in the 
ODI was converted to metric units of length. One mile, half a mile and 100 yards 
were converted to: two kilometres, one kilometre and 500 meters respectively. 
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Patients were encouraged to ask questions to clarify any aspect of the ODI they 
were unsure of. There was no time limit placed on patients for completion of 
responses to the ten items in the ODI and they returned the questionnaire to the PI 
once complete. The PI reviewed the completion of the questionnaire and clarified 
any potential areas of confusion with the patient in person – for example, where 
more than one answer was selected for each section.  
2.5.2. Pharmacological Data Collection 
The PI reviewed medical records and analysed the medication prescribed following 
the patients’ most recent visit to Spine OPD documenting the findings in the drug 
survey (Appendix E) as described below. The medication to take home (T.T.O.) was 
prescribed at the end of the consultation notes alongside which the pharmacist had 
documented the availability and quantity of drugs dispensed monthly through 
symbols and numbers (total number of pills was written adjacent to the specific 
medication).  
The appropriate number of pills required (as per the clinician’s prescription) was 
calculated. Where prescribed quantities matched that dispensed, “in stock” was 
documented in the drug survey adjacent the specific drug. Where the medication 
was not available (a stock out), and the symbol for it being out of stock “O/S” had 
been annotated and this was duly recorded. Any discrepancy in the quantity 
prescribed and that dispensed was documented as a “shortage”. 
As patients may have presented their file to the pharmacy several times since their 
previous clinical consultation and their presentation at the time of enrolment into the 
study (any number between one and six repeat T.T.O.’s), annotations from any 
single follow-up at the pharmacy was selected at random and documented.  
The drug survey form classified drugs into several groups. Under these groups, 
commonly available medication available within SA was classified and listed. The 
drugs were listed under a variety of trade and generic names to avoid confusion and 
aid ease of data capturing for later analysis. These names were compiled from the 
SA’s Monthly Index of Medical Specialities Desk Reference (MIMS). 
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These drug classes were listed as follows: 
 Paracetamol 
 NSAIDS 
 Opioids 
 Opioid-like drugs 
 Combinations 
 Muscle relaxants 
 Topical analgesics 
 Antiepileptics 
 Antidepressants 
 Antipsychotics 
2.5.3. Data sorting 
Patient information was subsequently captured using Research Electronic Data 
Capture (REDCap™) online software for analysis.  
The data sets obtained from 279 enrolled patients included: 
 Patient age 
 Patient gender 
 Responses to ODI items  
 Availability of prescribed drugs  
For each drug prescribed, availability was documented using the designations 1 (in 
stock), 2 (shortage) and 3 (stock out), ‘substituted’ (where the pharmacist had 
provided a similar class of drug to that prescribed due to drug shortage) and where 
drug status was not recorded, this was listed as ‘not documented’. 
ODI responses were also captured in REDCap™ with responses to all items of the 
questionnaire (sex life item was optional) recorded. Each answer was allocated a 
number (0 to 5) with increasing value allocated to responses indicating progressively 
worse disability. 
2.6. Sample size 
A sample size calculation was conducted to establish the numbers needed to recruit. 
A confidence interval of 95% was used with an estimated ODI value of 43%5 in a 
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comparable population and a margin of error of 0.0598. The sample size calculation 
formula (n = Z2P (1-P)/e 2) where ‘n’ is sample size, P is estimated prevalence, ‘e’ is 
the margin of error and ‘Z2’ is the confidence interval was used. A minimum sample 
size of 192 was found to be representative of the population studied. The study 
managed to recruit 282 patients in total, three of whom were excluded due to several 
incomplete data sets. 
2.7. Data analysis 
Central tendencies of mean, standard deviation, median and interquartile range were 
used to summarise the data. Spearman’s rank correlation and Mann Whitney U tests 
were both used in this study to test the non-parametric data collected. The one way 
ANOVA test was also applied to determine significant statistical differences in the 
non-normal data collected. All statistical tests were analysed by using IBM SPSS 
Statistics ® 24.0.  
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3. CHAPTER THREE – RESULTS 
A total of 282 participants were recruited for the study. Only 279 participants were 
included in the data analysis. Three patients were excluded due to grossly 
incomplete responses.  
3.1. Demographics and descriptive analysis of participants 
3.1.1. Age 
The mean age of the included participants was 57.1 ± 12.6 years. The youngest and 
oldest participants were aged 20 and 92 years old respectively. 
3.1.2. Gender 
The majority (79.6%) of participants were female as shown in Figure 3.1 below. 
 
 
 
 
 
 
 
 
Figure 3.1: Participant gender distribution (N = 277) 
 
3.2. ODI score outcomes 
Of the 279 participants included in the study, only 42 participants completed the item 
related to their sex lives.  
The median (interquartile range) ODI score of the participants was 48.9% (27) with a 
25 - 75% interquartile range of 37.8 - 64.4%. 
The minimum and the maximum percentage ODI score were 11% and 96% 
respectively. More than a quarter of the participants reported moderate disability 
Male 
21% 
Female 
79% 
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(28%), severe disability (35.1%) and crippling disability (28%) as shown in Figure 3.2 
below.  
 
 
Figure 3.2: Participant ODI category (N = 279) 
 
3.2.1. Gender and ODI scores 
Table 3.1 below shows the ODI score with respect to the gender of the participants.  
Table 3.1: ODI scores according to gender  
 
 
 
As shown in Table 3.1, females reported a significantly higher ODI than males,         
p < 0.05.   
3.2.2. Age and ODI category 
Table 3.2 below shows the mean age of the participants classified according to the 
disability status.  
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Table 3.2: Age (in years) of participants according to ODI category  
  
Table 3.2 above shows that participants with minimal disability were younger (52.8 ± 
12.2) years than participants that reported moderate – severe disability. There was 
no significant difference in the disability status of the participants with respect to their 
age (p > 0.05).  
3.3. ODI item classification and responses 
The ODI items were classified into ‘Activity limitation’, ‘Participation restriction’ and 
‘Impairment’ according to the ICF disability classification 6, 7.  
 
3.3.1. Activity limitation 
Table 3.3 outlines the activity limitation related items in the Oswestry Disability Index, 
which are personal care, lifting, sleeping, travelling and walking.  
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Table 3.3: Activity limitation 
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Table 3.3b: Activity limitation (continued) 
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Table 3.3 shows the results of the activity limitation related components of the ODI. 
Pain was reported to limit physical activities, predominantly walking (55.6%) and 
standing (56.3%). Sitting for more than 30 minutes exacerbated pain in 27.2% of the 
participants and 62.4% of the participants could groom themselves with little or no 
pain.  
3.3.2. Participation restriction 
Table 3.4 outlines the limitation in social activities due to pain. 
Table 3.4: Participation restriction  
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As shown in Table 3.4, 43.8% of the participants reported limited or no social life 
because of pain. Only, 15.5% reported normal pain free social life. 
3.3.3. Impairment (Pain intensity) 
Table 3.5 outlines the severity of pain in the participants studied.  
Table 3.5: Impairment  
 
As shown in Table 3.5, 50.4% of the participants reported severe pain at the time of 
presentation. Pain intensity from the ODI was isolated and analysed.  
3.3.4. Pain intensity classified according to the ODI category 
Table 3.6 outlines the pain intensity of the participants according to their disability 
category. 
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Table 3.6: Pain intensity according to ODI category 
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As outlined in Table 3.6 above:  
 in participants with minimal disability (as determined by their ODI score), pain 
intensity was mainly mild (47.1%)  
 in participants with moderate disability, pain was mostly mild-moderate 
(63.7%) 
 in participants with severe disability, pain was moderate-fairly severe (63%)  
 in participants with crippling disability, pain was mostly fairly severe – very 
severe (71.8%)  
Spearman correlation coefficient showed significant moderate positive correlation 
between ODI score and pain intensity (rs = 0.61, p < 0.001).  
There was no significant correlation between age of the participants and the ODI 
score (rs = 0.03, p = 0.62).  
3.4. Association between pain, demographics and ODI items 
There was no significant correlation between age of the participants and the ODI 
score (rs = 0.03, p = 0.62). Further correlation analysis between the ODI items and 
pain is outlined in Table 3.7 below.  
Table 3.7: Correlation analysis between ODI items and pain 
 
 
 
 
 
 
 
As shown in Table 3.7 above, pain showed a weak, positive significant correlation 
with all the participation restriction and activity limitation (p < 0.05) except for the sex 
life category (p > 0.05).  
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3.5. Drug prescriptions 
Table 9 outlines the summary of the prescribed drug into broad categories – 
antidepressants, antiepileptics, antipsychotics, combinations, muscle relaxants, 
opioid-like drugs, paracetamol, topical drugs and NSAIDs.  
3.5.1. Generic and trade names of drugs prescribed  
Clinicians had prescribed drugs using both generic and trade names, but the drugs 
were analysed under the generic name of their active ingredient.  
 Paracetamol is the active ingredient in Painamol™ and Panado™. 
 Celebrex™ contained the active ingredient celecoxib - a COX-2 selective 
NSAID. 
 Diclofenac sodium is the active ingredient in Volatren™. 
 Ibuprofen is the active ingredient in Nurofen™ and Brufen™.  
 Indomethacin is the active ingredient in Arthrexin™, Arthrotec™ and 
Indocid™. 
 Mefenamic acid is the active ingredient in Fenamin™. 
 Piroxicam is the active ingredient in Feldene™ and Pixicam™. 
 Tramadol hydrochloride (tramadol) is the active ingredient in Tramal™. 
 Ibuprofen + paracetamol = Panado Plus™.  
 Paracetamol + codeine = Painamol Plus™/ Spectrapain Forte™ / Stillpane™ / 
Paracods™ 
 Diclofenac diethylamine (diclofenac) is the active ingredient in Voltaren 
Emulgel™, Panamor Gel™. 
 Methyl salicylate is the active ingredient in “rub rub”. 
 Carbamazepine is the active ingredient in Tegretol™. 
 Sodium valproate is the active ingredient in Epilim™. 
 Clonazepam is the active ingredient in Rivotril™. 
 Amitriptyline hydrochloride is the active ingredient in Trepiline™.  
 Aripiprazole is the active ingredient in Abilify™.  
3.6. Prescription Frequency by Drug Category 
Table 3.8 outlines the summary of the prescribed drugs. 
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Table 3.8: Summary of drug categories prescribed to participants 
 
 
 
 
 
 
 
As outlined in Table 3.8, opioid-like drugs (n = 239), non-steroidal anti-inflammatory 
drugs (n = 200) and antidepressants (n = 139) were the most commonly prescribed 
drugs.  
3.7. Drug Availability 
Table 3.9 (following page) outlines the availability of drugs for the participants. 
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Table 3.9: Drug availability 
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Table 3.9 above outlines the availability of the prescribed NSAIDs for the 
participants. Diclofenac was the most prescribed NSAID contributing to 65.2% of all 
the NSAIDs prescribed, and it was in stock 54.2% of the time.  
Paracetamol was prescribed a total of 101 times and there was a 77.2% shortage of 
the dose dispensed to the patients.  
Of the 98 combination drugs prescribed, 95.6% were paracetamol + codeine, and it 
experienced a shortage in 78.7% of the prescriptions fulfilled.  
3.8. Drug prescription and ODI status 
Table 3.10 outlines the frequency of the prescribed analgesic and the disability 
status of the participants.  
 
Table 3.10: Drug category prescribed to participants and disability category 
 
 
 
 
 
 
 
 
 
 
 
As shown in Table 3.10, in the participants with minimal – moderate disability, opioid-
like drugs (n = 74) and NSAIDs (n = 68) were mainly prescribed. Patients with 
severe and crippling disability were mainly prescribed opioid-like analgesics (n = 
156), NSAIDS (n = 125) and anti-depressants (n = 93). 
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4. CHAPTER FOUR – DISCUSSION  
4.1. Disability Status and pain intensity of patients with cLBP 
This study examined the disability status of patients treated at the spine OPD for 
cLBP. It also assessed whether patients received the prescribed medication to 
manage their cLBP and, furthermore, analysed clinicians’ prescribing habits. 
A median disability score of 48.9% was reported among the participants in this study, 
whereas, an average ODI score of 43.3% was reported in one meta-analysis among 
chronic back pain patients receiving treatment99 . This study showed slightly higher 
than the average disability scores, relative to other cLBP studies, where post-
therapeutic disability was analysed5, 100, 101. 
In line with preceding studies, chronic back pain showed a significant effect in 
limiting several activities of daily living in participants102-104. The pain intensity item of 
the ODI questionnaire was used as a comparative item as well as an outcome 
measure in this study in documenting the severity of pain in the patients enrolled in 
this study. Pain intensity ratings leant towards the higher end of the scale, with 73% 
of patients reporting pain intensity as being ‘moderate’ to ‘very severe’. The resultant 
outcome of chronic back pain was found in limited function and reduced activities of 
daily living due to pain, ultimately causing patient disability102-104. The ODI scores in 
this study classified 56% of enrolled patients as suffering from ‘moderate’ to 
‘crippling’ disability.  The increase in pain in our study was directly proportional to an 
increase in disability105. The investigators reasoned that, adequate pain 
management would reduce discomfort and pain, hence eventually reducing disability 
with improved quality of life106. 
 
One of the most affected activities of daily living reported in this study was mobility.  
Approximately fifty six percent (55.6%) of patients required the use of a walking aid 
and/or could not walk a distance of 500m without discomfort or pain. In contrast, 
70.6% of patients were capable of standing for more than half an hour without pain. 
With a slow cadence of gait in cLBP, these altered biomechanics of the lower back 
and increased spinal loading elicited pain when walking rather than an upright 
posture alone would have done49, 50. In a not too dissimilar fashion, increased spinal 
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loading on lifting objects worsened back pain as evidenced by a significant 
proportion of patients who reported an ability to carry only light objects (58.1%).   
Sitting was modestly impaired. While well over half (62.4%) of patients reported 
being able to sit as long as they wished, most of these patients (38.4%) reported a 
preferred type of seat. With respect to travel, most patients (53%) were able to take 
journeys of over two hours with their lumbar spine kept in relative lumbar flexion 
while presumably seated. 
The nominal effect of pain was further evidenced by data on sleeping habits. A large 
sum of patients (46.2%) reported being able to sleep well unaffected by, or with 
minimally disrupted sleep, in spite of pain. Similarly, social life was another item 
disproportionately affected - 50% of patients maintained a normal social life despite 
aforementioned ‘severe disability’ or ‘crippling’ pain.   
 
Personal care remained largely unaltered for a majority of patients, with 62.4% 
reporting normal grooming habits without, or despite, pain. This was presumptively 
because their posture (standing upright or sitting down) while getting dressed, did 
not exacerbate  
It was found that pain had no correlation with the sex life category (p>0.05). It should 
be noted that only 42 (15%) of the participants responded to this question. The 
relatively small number of patients who elected to complete this item made us 
question the statistical value of our findings. Several studies cite local (South African) 
and global cultural taboos surrounding discussions about sex, to explain their 
similarly low response rate to this particular ODI item107-110. Some researchers even 
questioned the inclusion of this item in the ODI, citing the concern that its inclusion 
may be discouraging patients from participating in the questionnaire entirely110. 
These social norms were, presumably, the cause of the meagre response rate to this 
question in this study. 
Although this study did not objectively document the ambulatory status of 
participants, researchers anecdotally reported that a majority of patients recruited for 
this study were mobile and most had walked several hundred meters through the 
hospital building to access the Spine clinic. In contrast, a large percentage of 
participants’ results suggested that patients suffered ‘crippling’ symptoms, and that 
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their pain had caused them to be ‘bed ridden’. The raised median functional disability 
scores in our study population, conflicted findings that indicated a majority of 
participants coped well in most (five out of eight) ‘activities’ and did well in the 
‘participation’ item.  
 
Several possible reasons for this apparent discrepancy were entertained. Firstly, the 
self-reported nature of the study lent itself to inaccuracies. This notion was 
consistent with other studies based on self-reported data111, 112.  
 
Medical literature has identified catastrophising of pain as a coping mechanism in 
patients. Albeit, a maladaptive technique found in patients suffering from chronic 
pain, this problematic technique has been well recognised as a potential reason 
behind higher pain, and hence disability, scores111.  
 
The majority (79.6%) of participants were female in this study. A statistically 
significant difference was found between the ODI scores of females in comparison to 
the males. Females had a median ODI score of 53.3% and males 40.0%. This 
gender disparity was consistent with several studies and large scale trials on LBP, in 
which females reported higher pain intensity, disability and interference with activity 
of pain, than men113, 114. Given the significant number of female participants, their 
higher scores would have raised the median ODI in this study.  
 
Chronic pain is more disabling for women than men for the same condition115, 116. 
Pain also has a raised prevalence in women attributed to gender differences in 
coping strategies, and higher rates of catastrophising in women115, 116. Various 
responses to drug therapies differ between males and females. Although it is unclear 
why, women have been shown to respond better to morphine analgesia than with 
other types of analgesia116. Additionally, hormonal changes have been associated 
with an increased incidence of back pain in peri- and post-menopausal women117. 
These hormonal changes are associated with an increased risk of co-morbidities 
such as osteopaenia and osteoporosis, which, by definition, increase the risk of 
vertebral fractures117.  
 
Women, in general, demonstrate better health-seeking behaviour than men and 
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have historically been reliable in attending to their health care concerns 118. This is 
evidenced by the fact that, even when corrected for female-specific conditions, 
women visit health care providers more often, and even have longer consultation 
times than men119. This is, perhaps, why this study enrolled a significant number of 
women.  
 
Although race was not documented, the local population in Soweto served by 
CHBAH is predominantly Black (98.4%)120. American literature on the association 
between race and a perception of pain suggests that historically, socially 
disadvantaged populations – Blacks, Hispanics and Asians - reported higher pain 
intensity, disability and interference of pain with activity compared to other racial 
groups121-123. Our patients’ demographic background – particularly in the light of their 
upbringing in a racially segregated society – may have influenced their perception of 
pain123. 
Another potential reason for higher pain scores was the likelihood of secondary 
gain124-127. Patients enrolled may have embellished their responses in order to 
influence the clinician’s documentation of symptoms on their disability grant 
application. Soweto, as an economically impoverished precinct of Johannesburg, 
has a significantly indigent population. In SA, women have higher unemployment 
rates128. Disability in this population has an untold a knock-on effect on the local 
economy through lost productivity and a raised demand on healthcare systems and 
social services126.  
 
Women earn less and experience worse states of poverty than men and male-
headed households do128. Furthermore, nationwide, a significant proportion of grant 
recipients are Black women (63.4% of whom live below the poverty line) 128. Without 
trivialising the disability brought on by cLBP, the physical limitation associated with 
pain would exacerbate female patients’ difficulty in finding or keeping employment, 
so, while their symptoms with activities of daily living may be tolerable, manual 
labour may exacerbate their cLBP, thus necessitating an increasing dependency on 
social grants. The disadvantaged socioeconomic status of our patient population 
could result in malnutrition.  
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The impeding effect of raising children on women’s careers, also distributes the 
working population of women towards their middle age. Approximately 30% of 
employed women in SA are at least 45 years old128. The impact of LBP in a 
socioeconomically active population would have a negative knock-on effect on SA’s 
economy due to absence from work, inability to return to work and increased 
dependency on social grants. While information on financial and employment status 
was neither sought after by investigators in this study, nor had investigators any 
influence on treating clinicians’ opinions with respect to disability grant applications, it 
is possible, however, that patients may have overstated the severity of their pain.  
 
Lastly, the raised ODI median found in this study may also have been as a result of 
drug shortages. While patients with acute LBP present with relatively high ODI 
scores that improve with time, our population appears to have failed to follow a 
similar improving pattern, possibly due to lack of access to therapeutic drugs as a 
consequence of health care system failures. It is probable that the incongruous 
results are as a result of both erratic drug availability and selective use of analgesics 
by patients. It is entirely conceivable that the shortages would force patients to ration 
their use of analgesics, preferring to use them on certain occasions rather than to 
maintain pain control. These occasions may be saving analgesia for use exclusively 
before bed, prior to travel or attending social events.  
 
The population studied comprised predominantly of a middle aged population with a 
mean age of 57.1 ± 12.6 years. The youngest and oldest participants were aged 20 
and 92 years old respectively. While the data showed that participants with minimal 
disability were younger (52.8 ± 12.2 years) than those who reported ‘moderate’ to 
‘severe’ disability, there was no significant difference in the disability status of the 
participants with respect to their age (p > 0.05) and no significant correlation 
between age of the participants and the ODI score (rs = 0.03, p = 0.62).  
 
While LBP generally shows a higher prevalence in older adults, our study was 
unable to replicate this. This may potentially have been because the sampling 
method used in this study was purposive in nature113, 129. By default, investigators 
may have been more likely to interact with a certain age of patients owing to patient 
level of literacy, willingness and ability to engage in turn with investigators, lending 
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bias to the age group enrolled. As a significant proportion of patients were of a 
similar age, no statistically significant correlation between age and disability to 
function was found. 
4.2. Prescribed Medication 
Clinicians followed local and international guidelines in their prescribing habits. While 
paracetamol was prescribed to patients, it was always recommended for use in 
concert with other drugs (NSAIDS, tramadol, trepiline etc.). 
Opioid-like drugs (n = 239), NSAIDS (n = 200), antidepressants (n = 139) and 
paracetamol (n = 100) were the top four most prescribed drugs. Patients with 
‘severe’ and ‘crippling’ disability were mainly prescribed opioid-like analgesics (n = 
156), NSAIDS (n = 125) and anti-depressants (n = 93) and paracetamol (n = 66).  
Diclofenac sodium was the most prescribed NSAID in this study - contributing to 
65.2% of all the NSAIDs prescribed. Clinicians prescribed diclofenac nearly five 
times more often than any other NSAID, but it was in stock and available as 
prescribed only 54.2% of the time. In fact, nearly every NSAID prescribed 
experienced shortages, except Fenamin™ (mefenamic acid), which was prescribed 
(and readily available) once.  
Patients with ‘severe’ and ‘crippling’ disability were most likely to be prescribed anti-
depressants (n = 93), while those with crippling pain received the bulk of 
antiepileptics prescribed (n = 13). 
Paracetamol was prescribed a total of 101 times during this study, but there was a 
shortage of the drug for 77.2% of patients. In order to benefit from the use of this 
drug, patients would be required to take up to the maximum daily recommended 
dose of 4 000mg70.  
Of the 98 combination drugs prescribed in this study, 95.6% were paracetamol and 
codeine, which experienced a shortage in 78.7% of the prescriptions fulfilled.  
Muscle relaxants were among the least prescribed drug (n = 10). Opioids were not 
prescribed for any patient in the study. 
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Topical medication was prescribed for 63 patients, likely for patient self-massage or 
for a family member to use in a simplified version of physical therapy at home. Their 
biochemical action has not been proven to improve symptoms in cLBP. 
With the exception of the use of rubefacients in 23% of patients, the study found that 
clinicians prescribing habits followed evidence based guidelines. 
4.3. Conclusion  
To the best knowledge of the investigators, this is the largest study to date, analysing 
cLBP symptoms in an out patient population in South Africa. It is also the largest, 
formally documented survey of drug shortages at a single centre in South Africa. 
Relative to other studies using ODI scores to analyse patient outcomes, an above-
average disability score median of 48.9% was found.  
The investigators believed that the significant disability described was aggravated by 
an inadequate supply of pain medication. Notwithstanding the adverse influence of 
disability on the South African economy, the current health care system appears to 
be failing to meet the needs of a significant population suffering with chronic LBP. 
Clinicians prescribing habits followed evidence based guidelines - with the exception 
of the use of rubefacients in approximately 23% of patients. Tramadol was the most 
prescribed drug overall and was followed by NSAIDS in combination with other 
drugs. Despite the preferential use of tramadol, it was only available as prescribed 
7% of the time. Paracetamol was available only 23% of the time and prescribed, and 
non-steroidal anti-inflammatories freely accessible only 46% of the time. 
4.4. Limitations and recommendations 
The limitations encountered during this study were that a self-administered 
assessment was used rather than the clinician’s subjective analysis of pain. A single 
ODI also has limited value in assessing patient response to treatment, however ODI 
questionnaires should be filled out at primary care clinics prior to therapy and referral 
to secondary or tertiary medical institutions to aid in analysing response to therapy 
and disability status. 
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Drug supply issues should be redressed at every level of healthcare in SA. It is clear 
that the current steps taken to resolve chronic drug shortages and stock-outs have 
failed. 
Future studies on back pain management in our setting should be expanded to 
include the contribution of allied and alternative health care options in the 
management of cLBP. 
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APPENDIX A: PATIENT INFORMATION/CONSENT SHEET 
 
Dear Patient, I am Dr. Anne Maina, a registered medical doctor practicing as an 
orthopaedic registrar at Chris Hani Baragwanath Academic Hospital (CHBAH). You 
are invited to volunteer for a research study which I, Dr. Maina, am conducting as the 
Chief Investigator with the assistance of a spine specialist, Dr. Ukunda as well as the 
Head of Clinical Orthopaedic Service, Prof. Ramokgopa. This will be done with the 
help of Orthopaedic Registrars and Medical Officers working in the spine unit. This 
form is to help you decide if you would like to participate. Before you agree to take 
part in this study, you should fully understand what is involved. If you have any 
questions that are not answered in this document, do not hesitate to ask your 
treating doctor or me. You should not agree to take part unless you are completely 
happy with the process involved. 
What is the purpose of this study? You have been diagnosed as suffering with low 
back pain and the investigator would like you to consider answering two 
questionnaires that involve determining how severe your low back pain has been in 
the three months as well as the medicine you have taken over the same time.  
How long will it take for me to complete the questionnaire? It will take you ten 
minutes to complete the back pain questionnaire. 
Has this study received ethical approval? This study Protocol has been submitted 
to the Faculty of Health Research Ethics Committee (Medical), University of 
Witwatersrand.  Written approval to conduct this study has been granted by the 
Health Research Ethics Committee (HREC). The study has been structured in 
accordance with the Declaration of Helsinki (last update: October 2008), which deals 
with the recommendations guiding doctors in biomedical research involving 
human/subjects. A copy of the Declaration may be obtained from me should you 
wish to review it. To contact the HREC directly, please call Prof. Cleaton-Jones on 
011 717 2301, email: peter.cleaton-jones1@wits.ac.za alternatively contact the 
administrative officers Ms. Z. Ndlovu / Mr. Rhulani Mkansi / Mr. Lebo Moeng on 011 
717 2700 / 2656 / 1234 / 1252; email zanele.ndlovu@wits.ac.za, 
rhulanimkansi@wits.ac.za or lebo.moeng@wits.ac.za. Protocol reference number: 
M160406 
What are my rights as a participant in this study?  Your participation is entirely 
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voluntary and you can refuse to participate or stop at any time without stating any 
reason. Your withdrawal will not affect your access to medical care at CHBAH. If it is 
discovered that you did not give an accurate indication of medication taken or did not 
follow the instructions provided on the questionnaires, you may be withdrawn from 
the study at any time. 
Financial arrangements: There is no financial reimbursement for participating in 
this study. Neither you nor CHBAH are required to make any payment to participate 
in this study. 
Source of additional information: These questionnaires are distributed by, and will 
be collected and assessed by me. The collection of information for this study will be 
conducted with the assistance of spine specialist Dr Ukunda and other orthopaedic 
doctors working in the spine unit. If at any time you have any questions or concerns 
about the study, please do not hesitate to contact me on 011 933 8914. 
Confidentiality:  All information obtained from these questionnaires is strictly 
confidential. Data that may be reported in scientific journals will not include any 
information that identifies you as a patient in this study. Any information regarding 
your treatments and condition will be held in the strictest confidence.  
Informed consent: I hereby confirm that I have been informed by the treating 
doctor, about the nature, conduct, benefits and risks of this study on management of 
my back pain. I have also received, read and understood the above information 
leaflet regarding this study. I am aware that the results of this study including my 
patient number, age and sex will be anonymously processed into a study report. I 
may at any stage, without prejudice, withdraw my consent and participation in the 
trial. 
I have had sufficient opportunity to ask questions and (of my own free will) declare 
myself prepared to participate in the study. 
Patients full name: ______________________________________________ 
Patients ID number: _____________________________________________ 
Patients signature:  __________________ Date: ______________________ 
I, Dr. ____________________________________ herewith confirm that the above 
patient has been fully informed about the nature and conduct of this study. 
Investigators name: _____________________________________________ 
Investigators signature: ________________Date: ______________________ 
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Translators name: _______________________________________________ 
Translators signature: ____________________________________________ 
Witness name: _________________________________________________ 
Witness signature: ____________________Date: ______________________ 
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APPENDIX B: PATIENT CONSENT FORM FOR ANOTHER PERSON 
TO ACCESS THEIR MEDICAL RECORDS 
 
Patient consent form for another person to access their medical records 
Patient Details 
Surname  
First Names  
Date of Birth  Sex  
Address  
Contact Number  
Details of persons to be given access to this patient’s information 
Full Name Dr. A. Maina, Dr. F. Ukunda, Prof. M. T. Ramokgopa and 
attending doctors at the Chris Hani Baragwanath Spine 
OPD 
Address Chris Hani Baragwanath Academic Hospital, Soweto 
Contact: 011 933 8914 
I confirm that I give permission for Chris Hani Baragwanath Academic 
Hospital to communicate with the persons identified above in regards to my 
medical records. 
 Signature  
      Date  
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APPENDIX C: INFORMED CONSENT SOURCE DOCUMENT 
 
Informed consent source document 
Full Patient Name: Patient ID number: 
Patient No.: Protocol No.: M160406 
Date consent obtained:  Time consent obtained:  
Name of person who explained study:  
Subject verbalised understanding of risks, benefits and other relevant issues.  
Initials:  Date: 
All questions and concerns addressed and answered to the patient’s satisfaction.  
Initials:  Date: 
Patient stated they understood they would receive standard medical care regardless 
of participation in study 
Initials:  Date: 
Patient verbalized understanding that they could withdraw consent at any time. 
Initials:  Date: 
Patient given a copy of the signed and dated information and consent form 
Initials:  Date: 
Patient signed a copy permitting access to their medical records. 
Initials:  Date: 
No research study procedures done prior to consenting 
Initials:  Date: 
Comments:  
Translator Name: Translator Signature: 
Witness 1 Name: Witness 1 Signature: 
Witness 2 Name: Witness 2 Signature: 
Signature of investigator:                                                 Date:  
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APPENDIX D: OSWESTRY LOW BACK PAIN DISABILITY 
QUESTIONNAIRE 
 
Oswestry Low Back Pain Disability Questionnaire 
Patient number:    Age:    Sex: Female/Male 
Instructions: This questionnaire has been designed to give us information on how 
your low back pain is affecting you every day. Please check ONE statement in each 
section that best describes how your low back pain has affected you over the last 
seven (7) days.  
Section 1 – Pain intensity 
 I have no pain at the moment  
 The pain is very mild at the moment  
 The pain is moderate at the moment  
 The pain is fairly severe at the moment  
 The pain is very severe at the moment 
 The pain is the worst imaginable at the moment 
Section 2 – Personal care (washing, dressing etc.) 
 I can look after myself normally without causing extra pain 
 I can look after myself normally but it is very painful 
 It is painful to look after myself and I am slow and careful 
 I need some help but manage most of my personal care 
 I need help every day in most aspects of self-care 
 I do not get dressed, I wash with difficulty and stay in bed 
Section 3 – Lifting 
 I can lift heavy weights without extra pain  
 I can lift heavy weights but it gives extra pain 
 Pain prevents me from lifting heavy weights off the floor, but I can 
manage if they are conveniently placed e.g. on a table 
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 Pain prevents me from lifting heavy weights, but I can manage light to 
medium weights if they are conveniently positioned 
 I can lift very light weights  
 I cannot lift or carry anything at all 
Section 4 – Walking* 
 Pain does not prevent me walking any distance 
 Pain prevents me from walking more than 2 kilometers 
 Pain prevents me from walking more than 1 kilometer 
 Pain prevents me from walking more than 500 meters 
 I can only walk using a stick or crutches  
 I am in bed most of the time and have to crawl to the toilet 
Section 5 – Sitting 
 I can sit in any chair as long as I like 
 I can only sit in my favourite chair as long as I like 
 Pain prevents me sitting more than 1 hour 
 Pain prevents me from sitting more than half an hour 
 Pain prevents me from sitting more than 10 minutes 
 Pain prevents me from sitting at all 
Section 6 – Standing 
 I can stand as long as I want without extra pain 
 I can stand as long as I want but it gives me extra pain 
 Pain prevents me from standing more than 1 hour 
 Pain prevents me from standing more than 30 minutes 
 Pain prevents me from standing more than 10 minutes 
 Pain prevents me from standing at all 
Section 7 – Sleeping 
 My sleep is never disturbed by pain  
 My sleep is occasionally disturbed by pain  
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 Because of pain I have less than 6 hours sleep  
 Because of pain I have less than 4 hours sleep  
 Because of pain I have less than 2 hours sleep  
 Pain prevents me from sleeping at all 
Section 8 – Sex life (if applicable) 
 My sex life is normal and causes no extra pain 
 My sex life is normal but causes some extra pain 
 My sex life is nearly normal but is very painful  
 My sex life is severely restricted by pain  
 My sex life is nearly absent because of pain  
 Pain prevents any sex life at all 
Section 9 – Social life 
 My social life is normal and gives me no extra pain 
 My social life is normal but increases the degree of pain 
 Pain has no significant effect on my social life apart from limiting my 
more energetic interests e.g. sport 
 Pain has restricted my social life and I do not go out as often 
 Pain has restricted my social life to my home  
 I have no social life because of pain 
Section 10 – Traveling 
 I can travel anywhere without pain  
 I can travel anywhere but it gives me extra pain 
 Pain is bad but I manage journeys over two hours 
 Pain restricts me to journeys of less than one hour 
 Pain restricts me to short necessary journeys under 30 minutes 
 Pain prevents me from traveling except to receive treatment 
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APPENDIX E: MEDICATION SURVEY 
 
Medication Survey  
Patient number: Age: Sex: Female/Male 
Instructions 
This questionnaire has been designed to give the investigators information on 
how much and what medication the patient takes for his/her back pain.  
1. Circle the drug(s) in each section that the patient is taking for their pain (there 
may be more than one medicine in each section). 
2. Draw a line connecting the drug to the dose of medication that is taken daily or 
regularly (i.e. more than 3 days in a week).  
4. If there are drugs prescribed but not dispensed due to “stock outs” (indicated 
by the symbol “O/S”) indicate how long (weeks/months) the patient did not have 
access to this medicine over the last three (3) months 
5. If you note any discrepancy between the volume prescribed and volume 
dispensed indicate this using the means described above. 
Medication Type and name 
(please circle applicable medication taken) 
Dose (no. 
tabs/caps/supps) 
No. of times 
taken/day 
PARACETAMOL:  
Napamol, Painamol, Panado, Paracetamol, 
Prolief 
  
NSAIDS:  
Advil, Aleve, Arcoxia, Arthrexin, Arthrotec, 
Betacin, Betagesic, Betaprofen, Brexecam, 
Brufen, Catafast, Cataflam D, Celebrex, 
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Coxflam, Disprin, Tora-Dol, Diclofenac, 
Dicloflam, Diclohexal, Dynak-50, Ecotrin, 
Fenamin, Flamecid, Flexocam, Fortfen, 
Iboflam, Ibucine, Ibuprofen, Indomethacin, 
Inza, K-fenak, Ketoflam, Loxiflam, Mefenamic 
acid, M-cam, Medoxicam, Meloxicam, Mobic, 
Nafasol, Napflam, Nurofen, Painil, Ponac, 
Ponstan, Ponstel, Panamor, Naproxen, 
Pixicam, Pyrocaps, Ranfen, Rayzon, 
Rheugesic, Synflex, Veltex, Vimovo, Voltaren, 
Xefo   
OPIOIDS:  
Adco Tenyl, Cyclimorph, DF-118, Durogesic, 
Jurnista, Morphine MST, Ompon, Oxycontin, 
Oxynorm, SRM Rhotard, Subutex, Temgesic 
  
OPIOID-LIKE:  
Dolotram, Domadol, Methadone, Nobligan, 
Tramahexal, Tramadol, Tramal, Tramaspen, 
Tramazac, Tramagesic  
 
  
COMBINATIONS:  
Abflex-4, Acurate, Adco-Dol, Adco-Napacod, 
Aco-Payne, Adco-Salterpyn, Antipyn Forte, 
Ban Pain, Besemax, Betapyn, Co-codamol, 
Codoxol, Compral, Dentopain, Doxyfene, 
Empacod, Excedrin, Gen Payne, Go-Pain, 
Ibucod, Ibumol, Ibupain, Lenadol, Lenapain, 
Lentogesic, Lotem, Meprogesic, Mepromol, 
Mybucod, Mybulen, Mypaid, Myprodol, Norflex 
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Co, Painagon, Painamol Plus, Panado Plus, 
Propain, Pynmed, Pynstop, Spasmend, 
Spectrapain Forte, Stilpane, Stopayne,  
Suncodin, Synaleve, Synap Forte, Syndol, 
Tensolve, Tensopyn, Tenston, Tramacet 
MUSCLE RELAXANTS: 
Baclofen, Lioresal, Myprocam, Norflex, 
Robaxin 
  
TOPICAL:  
Sovenor, Counterpain, Diclohexal gel, Fastum, 
Panamor gel, Reparil gel, Rheugesisc, 
Transact, Voltaren Emulgel, “Rub Rub” 
  
ANTIEPILEPTICS:  
Carbamazepine, Convulex, Degranol, 
Epanutin, Epilim, Epilizine, Epiproate, Epitec, 
Epitoz, Epleptin, Keppra, Lamictin, Lamidus, 
Lamitor, Lamotrigine, Levetiracetam, Lyrica, 
Mysoline, Navalpro, Neurontin,  Phenytoin, 
Redilev, Rivotril, Sabril, Tegretol, Topalex, 
Topamax, Topiramate, Toplep, Trileptal, 
Zarontin 
  
ANTIDPRESSANTS:  
Amitriptyline, Anafranil, Aropax, Camcolit, 
Cilate, Cilift, Ciloram, Cipralex, Cipramil, 
Citalohexal, Citalopram, Citraz, Cymbalta, 
Cymgen, Deparoc, Depnil, Depramil, 
Deprozan, Edronax, Efegen, Efexor, Emdalen, 
Equinorm, Escitalopram, Ethipramine, 
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Faveran, Fluoxetine, Flutinol, Fluvoxamine, 
Illovex, Lantanon, Lexamil, Limbitrol, Lorien, 
Ludiomil, Luvox, Mirteron, Mirtazapine, 
Molipaxin, Mytra, Nuzak, Odiven,  Parax, 
Paroxetine, Paxil, Parnate, Prohexal, Prozac, 
Ramure, Ranflocs, Remeron, Rezak, Scripto-
metic, Serdep, Serlife, Sertra, Sertraline, 
Talomil, Thaden, Tofranil, Traxodone, 
Trepiline, Trizac, Tydamine, Valdoxane, 
Venlafaxine, Venlor, Wellbutrin, Xet, Zolid, 
Yelate, Zoloft, Zosert, Zydus, Zylin, Zytomil 
ANTIPSYCHOTICS: 
Abilify, Cloment, Clopixol, Clozapine, 
Dopaquel, Eglonyl, Espiride, Etomine, 
Fluanxol, Geodon, Haloperidol, Invega,  
Largactil, Leponex, Modecate, Oleanz, Olexar, 
Orap, Perizal, Psyquet, Quetiapine, Redilanz, 
Risinia, Rispacor, Risperidal, Risperidone, 
Risperlet, Risponz, Rutra, Schizorol, 
Scriptometic, Serenace, Serez, Seroquel, 
Solian, Stelazine, Sulpiride, Truvain, Xepilon, 
Zoxadon, Zyprexa 
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APPENDIX F: CONFIRMATION OF STUDY APPROVAL (WITS 
HUMAN RESEARCH AND ETHICS COMMITTEE) 
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APPENDIX G: PERMISSION TO CONDUCT RESEARCH (MEDICAL 
ADVISORY COMMITTEE, CHRIS HANI BARAGWANATH 
ACADEMIC HOSPITAL) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
